trametinib dimethyl sulfoxide
chemical compound
Ratings
0
Nobody has rated this yet. Be the first!
GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
Pomalidomide, dabrafenib mesylate, and trametinib dimethyl sulfoxide
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor
